US Supreme Court may have to settle dispute over patenting DNA sequences
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6187 (Published 27 September 2011) Cite this as: BMJ 2011;343:d6187- Clare Dyer
- 1BMJ
The US Supreme Court may be asked to rule whether isolated sequences of DNA can be patented, in a challenge to a controversial patent conferring a US monopoly on testing for gene mutations that increase women’s risk of developing breast and ovarian cancer.
The American Civil Liberties Union and the Public Patent Foundation brought the lawsuit in 2009, together with the Association for Molecular Pathology, doctors’ organisations, patient advocacy groups, and individual doctors and patients. They argued that patents covering the BRCA1 and BRCA2 genes, granted in 1998 to the biotechnology firm Myriad Genetics and the University of Utah, were unlawful and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.